Maxim Biomedical, Inc. Secures $49.5 Million Manufacturing Award from U.S. HHS to Strengthen Pandemic Testing Efforts
Summary
ROCKVILLE, Md., Jan. 4, 2024 /PRNewswire/ -- MaximBio, a leading Maryland-based manufacturer specializing in lateral flow and diagnostic devices, is announcing the receipt of a $49.5 million award from the U.S. Department of Health and Human Services (HHS) through the Administration for Strategic Preparedness and Response (ASPR). This funding is designated to fortify the domestic manufacturing capabilities for diagnostic tests and enhance preparedness for potential future pandemics. The funding from ASPR underscores MaximBios commitment to advancing public health and strengthening the domestic supply chain. "We are proud to be playing a crucial role in the nations response to the ongoing health crises and fortifying our defenses against potential future pandemics. With a commitment to advancing public health, MaximBio specializes in the production of high-quality diagnostic tools that play a crucial role in disease detection and management.